IL18 and hepatocellular carcinoma: NLRC3 can effectively control the inflammatory response by negatively regulating the NF-κB signaling pathway and coordinating the interaction between caspase 1, IL-1β, and IL-18 expression, suggesting that NLRC3 may further increase the survival of HCC patients with a history of liver cirrhosis by reducing inflammation (24, 25).